SOHO Action Center
Welcome to the SOHO Action Center, your destination for the latest updates from the Society of Hematologic Oncology (SOHO) Annual Meeting. Here, you’ll find recaps of the conference’s most important sessions, giving you timely access to the data, insights, and perspectives shaping the future of blood cancer care.
1-12 of 12
Myeloid Mutations in ALL: Disease Risk and Prognostic Implications
Project Oncology®Myeloid Mutations in ALL: Disease Risk and Prognostic Implications
Caner Saygin, MD
Moving Beyond Chemotherapy in Mantle Cell Lymphoma Care
Project Oncology®Moving Beyond Chemotherapy in Mantle Cell Lymphoma Care
Jonathon Cohen, MD, MS
Supportive Care Before CLL Treatment: Infection Risk and Comorbidity Management
Project Oncology®Supportive Care Before CLL Treatment: Infection Risk and Comorbidity Management
Kerry A. Rogers, MD
How Myeloid Mutations in ALL Inform Treatment Decisions
Project Oncology®How Myeloid Mutations in ALL Inform Treatment Decisions
Caner Saygin, MD
Supportive Care During and After CLL Treatment: What to Prioritize
Project Oncology®Supportive Care During and After CLL Treatment: What to Prioritize
Kerry A. Rogers, MD
Key Questions Shaping Chemotherapy-Free Treatment in Mantle Cell Lymphoma
Project Oncology®Key Questions Shaping Chemotherapy-Free Treatment in Mantle Cell Lymphoma
Jonathon B. Cohen, MD, MS
- advertisement
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Project Oncology®Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Hallie Blevins, PhD
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Project Oncology®Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Ryan Quigley
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Project Oncology®Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Marlene Mimi Maeusli, PhD.
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Project Oncology®Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Project Oncology®Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
Project Oncology®Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
- advertisement